Research
New class of drugs may help treat Alzheimer’s disease
A new study has licensed a new class of drugs that may be able to treat Alzheimer’s disease.

Researchers have identified a new class of drugs that may be able to treat Alzheimer’s disease.
Researchers from the University of Arizona have developed a new class of drugs that could be used to treat degenerative neurological diseases and conditions such as Alzheimer’s disease.
The new class of drugs is able to cross the blood-brain barrier which has a main role in degenerative neurological conditions.
Neurological disorders are the leading cause of disability and the second leading cause of death worldwide. Brain disorders like Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, traumatic brain injury and stroke affect over eight million people in the United States each year and have limited effective treatments.
One the reasons for the lack of treatment is the body’s natural defence mechanism because the brain is protected by a natural blood-brain barrier.
This blockade consists of a network of blood vessels and tissues that help keep harmful substances from entering the brain.
The challenge is that the blood-brain barrier keeps out naturally occurring compounds produced by the body that can be caused to treat neurological disorders. Researchers have been trying to find ways to alter these compounds so that can get through the wall.
With this new class of drugs, researchers demonstrated that they can now reach previously unreachable receptor targets in the brain.
“We’re excited about what we’re doing now, but we’re looking at hundreds of other peptides that the brain produces that are opening more and more possibilities,” said Robin Polt, one of the authors of the research.
Unfortunately, the exact cause of Alzheimer’s disease is not yet fully understood, although a number of things are thought to increase the risk of developing the condition.
Alzheimer’s disease is a progressive condition, which means the symptoms develop gradually over many years and eventually become more severe.
The risk of Alzheimer’s disease and other types of dementia increases with age, affecting an estimated one in 14 people over the age of 65 and one in every six people over the age of 80.
There’s currently no cure for Alzheimer’s disease, but medicines are available that relieve some of the symptoms.
News
Shingles vaccine may slow biological ageing in older adults
Research
Blood sugar spike after meals may increase Alzheimer’s risk

Sharp rises in blood sugar after meals may raise Alzheimer’s risk, according to genetic analysis of more than 350,000 adults.
The findings point to after-meal glucose, rather than overall blood sugar, as a possible factor in long-term brain health.
Researchers examined genetic and health data from over 350,000 UK Biobank participants aged 40 to 69, focusing on fasting glucose, insulin, and blood sugar measured two hours after eating.
The team used Mendelian randomisation, a genetic method that helps test whether biological traits may play a direct role in disease risk.
People with higher after-meal glucose had a 69 per cent higher risk of Alzheimer’s disease.
This pattern, known as postprandial hyperglycaemia (elevated blood sugar after eating), stood out as a key factor.
The increased risk was not explained by overall brain shrinkage (atrophy) or white matter damage, suggesting after-meal glucose may affect the brain through other pathways not yet fully understood.
Dr Andrew Mason, lead author, said: “This finding could help shape future prevention strategies, highlighting the importance of managing blood sugar not just overall, but specifically after meals.”
Dr Vicky Garfield, senior author, added: “We first need to replicate these results in other populations and ancestries to confirm the link and better understand the underlying biology.
“If validated, the study could pave the way for new approaches to reduce dementia risk in people with diabetes.”
Insights
Study reveals why memory declines with age

A recent international study that pooled brain scans and memory tests from thousands of adults has shed new light on how structural brain changes are tied to memory decline as people age.
The findings show that the connection between shrinking brain tissue and declining memory is nonlinear, stronger in older adults, and not solely driven by known Alzheimer’s-associated genes like APOE ε4.
This suggests that brain ageing is more complex than previously thought, and that memory vulnerability reflects broad structural changes across multiple regions, not just isolated pathology.
Alvaro Pascual-Leone, MD, PhD is senior scientist at the Hinda and Arthur Marcus Institute for Aging Research and medical director at the Deanna and Sidney Wolk Center for Memory Health.
The researcher said: “By integrating data across dozens of research cohorts, we now have the most detailed picture yet of how structural changes in the brain unfold with age and how they relate to memory.”
The study found that structural brain change associated with memory decline is widespread, rather than confined to a single region.
While the hippocampus showed the strongest association between volume loss and declining memory performance, many other cortical and subcortical regions also demonstrated significant relationships.
This suggests that cognitive decline in ageing reflects a distributed macrostructural brain vulnerability, rather than deterioration in a few specific brain regions.
The pattern across regions formed a gradient, with the hippocampus at the high end and progressively smaller but still meaningful effects across large portions of the brain.
Importantly, the relationship between regional brain atrophy and memory decline was not only variable across individuals but also highly nonlinear.
Individuals with above-average rates of structural loss experienced disproportionately greater declines in memory, suggesting that once brain shrinkage reaches higher levels, cognitive consequences accelerate rather than progress evenly.
This nonlinear pattern was consistent across multiple brain regions, reinforcing the conclusion that memory decline in cognitively healthy ageing is linked to global and network-level structural changes, with the hippocampus playing a particularly sensitive role but not acting alone.
Pascual-Leone said: “Cognitive decline and memory loss are not simply the consequence of ageing, but manifestations of individual predispositions and age-related processes enabling neurodegenerative processes and diseases.
“These results suggest that memory decline in ageing is not just about one region or one gene — it reflects a broad biological vulnerability in brain structure that accumulates over decades.
“Understanding this can help researchers identify individuals at risk early, and develop more precise and personalized interventions that support cognitive health across the lifespan and prevent cognitive disability.”
News2 weeks agoFDA clears automated brain fluid device
Markets & Industry2 weeks agoAgetech World’s latest innovation & investment round-up
News2 weeks agoInsilico signs US$888m oncology deal with Servier
News2 weeks agoFood preservatives linked to increased diabetes and cancer risk, study finds
Wellness2 weeks agoUK bans junk food ads before 9pm to protect child health
News1 week agoCaptioning glasses win AARP pitch at CES
Markets & Industry2 weeks agoGlobal longevity initiative launches North American chapter
Technology6 days agoInterview: GlycanAge launch first hospital-based tests















